Effects of perfluorohexane vapor in the treatment of experimental lung injury

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Jörg U. Bleyl - , University Hospital Carl Gustav Carus Dresden, Department of Anesthesiology and Intensive Care Medicine (Author)
  • Axel R. Heller - , University Hospital Carl Gustav Carus Dresden, Department of Anesthesiology and Intensive Care Medicine (Author)
  • Manuel Heintz - , University Hospital Carl Gustav Carus Dresden, Department of Anesthesiology and Intensive Care Medicine (Author)
  • Matthias Schlemmer - , University Hospital Carl Gustav Carus Dresden, Department of Anesthesiology and Intensive Care Medicine (Author)
  • Roland Koch - , Institute for Medical Informatics and Biometry (Author)
  • Marcelo Gama de Abreu - , Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus Dresden (Author)
  • Matthias Hübler - , University Hospital Carl Gustav Carus Dresden, Department of Anesthesiology and Intensive Care Medicine (Author)
  • Peter M. Spieth - , Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus Dresden, University of Toronto (Author)
  • Thea Koch - , Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus Dresden (Author)

Abstract

Rationale: We investigated the effects of vaporized perfluorohexane (PFH) on pulmonary vascular tone, pulmonary vascular resistance and peak inspiratory pressure as well as lipid mediator formation in the treatment of calcium ionophore induced lung injury in a model of the isolated perfused and ventilated rabbit lungs. Methods: Lung injury was induced in isolated perfused and ventilated rabbit lungs by calcium ionophore A23187. Lungs were treated with either 4.5 vol.% (4.5 vol.% PFH; n = 6) or 18 vol.% (18 vol.% PFH; n = 6) PFH. Six lungs remained untreated (Control). In addition 5 lungs (PFH-sham) remained uninjured receiving 18 vol.% PFH only. Mean pulmonary artery pressure (mPAP), peak inspiratory pressure (Pmax), and lung weight (weight) were monitored for 120 min. Experiments were terminated before when the increase in lung weight exceeded 40 g. Perfusate samples were taken at regular intervals for analysis of TXB2, 6-keto-PGF1 and LTB4. Results: Controls reached the study end point significantly earlier than both PFH groups. Significant differences were found for a weight gain of 10 g and 20 g between the control and the 4.5 vol.% PFH and the 18 vol.% PFH. Differences in mPAP were more pronounced in the 4.5 vol.% PFH. However increases in Pmax were more marked in 4.5 vol.% PFH. TXA2-, PGI2-, and LTB4-levels were significantly lower in PFH groups. Uninjured lungs remained unaffected by the presence of 18 vol.% PFH. Conclusion: Inflammatory lung injury was attenuated by the treatment with 4.5 vol.% PFH and 18 vol.% PFH vapor in the isolated perfused rabbit lung. Therapeutic effects were more pronounced with a concentration of 4.5 vol.% PFH.

Details

Original languageEnglish
Pages (from-to)450-455
Number of pages6
JournalPulmonary pharmacology and therapeutics
Volume23
Issue number5
Publication statusPublished - Oct 2010
Peer-reviewedYes

External IDs

PubMed 20362687
ORCID /0000-0003-3953-3253/work/167217383

Keywords

Keywords

  • Acute lung injury, Fluorocarbons, Isolated rabbit lung, Perfluorohexane vapor